Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03075826 · ClinicalTrials.gov registry record · Phase 2
A Phase II Study of SGI-110 in Philadelphia-Negative Myeloproliferative Neoplasms
A Phase 2 study, sponsored by Weill Medical College of Cornell University.
- Completed
- Registry status
- Phase 2
- Development phase
- 22
- Enrollment target
NCT03075826 is a Phase 2 study that has completed, run by Weill Medical College of Cornell University. The registered enrollment target is 22 participants.
The verdict
NCT03075826, a Phase 2 study, has completed, sponsored by Weill Medical College of Cornell University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 22 participants
- Enrollment target
Study Summary
* This is an open label single-arm, single-institution stud to evaluate the efficacy and safety of SGI-110 in Philadelphia chromosome negative (Ph-) Myeloproliferative Neoplasms (MPN) (excluding PV, ET and primary/secondary myelofibrosis). The study will enroll approximately 50 patients at the Weill Cornell Medical College. * Enrollment onto this clinical study is expected to be completed in approximately 36 months. The total study duration will depend on individual response, evidence of disease progression and tolerance. Participants will be followed monthly for six months after removal from study or until death, whichever occurs first. Key eligibility: * Confirmed diagnosis of Ph- MPN and had * No chemotherapy or radiation treatment within 2 weeks prior to study entry. * Subjects meet other protocol-defined criteria related to baseline screening procedures.
Interventions
- DRUG SGI-110
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2016-03-15 |
| Est. Completion | 2021-03-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03075826
The ClinicalTrials.gov registry entry for NCT03075826 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Weill Medical College of Cornell University, which has 701 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which SGI-110 is the first listed.
NCT03075826 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03075826 about?
NCT03075826 is a clinical study titled "A Phase II Study of SGI-110 in Philadelphia-Negative Myeloproliferative Neoplasms". * This is an open label single-arm, single-institution stud to evaluate the efficacy and safety of SGI-110 in Philadelphia chromosome negative (Ph-) Myeloproliferative Neoplasms (MPN) (excluding PV, ET and primary/secondary myelofibrosis). The study will enroll approximately 50 patients at the Weill...
What is the current status of trial NCT03075826?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 22 participants. The study started on 2016-03-15. Estimated completion is 2021-03-31.
What interventions are being tested in trial NCT03075826?
The interventions under investigation include: SGI-110 (DRUG).
Who is sponsoring clinical trial NCT03075826?
This trial is sponsored by Weill Medical College of Cornell University, which has 701 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.